The Latest Updates from ReSPECT Clinical Trials
PBC Funding Award
Exciting news yesterday as $PSTV was able to share our recent $3 Million DoD Award for our ReSPECT-PBC Pediatric Brain Cancer Trial. Stock Region Article: https://bit.ly/4b4OBXG #Nasdaq #ClinicalResearch #ClinicalTrial #PediatricOncology #BrainCancer
$3 Million DoD Grant
BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the...
“Thriving Together”
Come by our NEW booth at the Living Beyond Breast Cancer Metastatic Breast Cancer Conference this weekend! We have information about Leptomeningeal Metastases and our ongoing ReSPECT-LM Clinical Trial. See you there! 🎗️ ReSPECT-LM Website:...
Head for the Cure: North Texas
Join some of the Plus Therapeutics team at the Head for the Cure 5K - North Texas on May 4th! They will be out supporting the local community, cancer research, and "Defeating Brain Cancer Step by Step." We hope to see you there 🏃🏃♂️🏃♀️ Event information:...
Welcome Dr. Brenner!
#ICYMI: Plus Therapeutics added Dr. Andrew Brenner to our management team. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. Full Press...
LBBC Curtain Raiser
📣 Mark Your Calendars! Plus Therapeutics will be exhibiting at the @livingbeyondbc Thriving Together Metastatic Breast Cancer Conference, April 19-21. Come learn about our ReSPECT-LM clinical trial for Leptomeningeal Metastases and meet some of our team. Event...
PSTV Analysis
#ICYMI : "Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst...Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due to a...
https://twitter.com/plustxinc
Welcome Brenner and Blouw
We would like to officially welcome Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. to the Plus Therapeutics Management Team! “As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology,...
NCCN Poster
Our ReSPECT-LM Poster from the National Comprehensive Network (NCCN) Conference is now on our website at https://ir.plustherapeutics.com/presentations
NCCN Curtain Raiser
Visit our poster at the National Comprehensive Cancer Network® (NCCN®) conference today and say hello to our clinical team! The poster will be available on our website after the conference
Plus Approach
Plus Therapeutics' novel approach to treating Glioblastoma overcomes the limitations of all three currently employed treatment modalities. Leveraging established, targeted delivery techniques, we seek to inject high doses of radiation directly into or near a cancer...
Welcome Frank
We are pleased to introduce Frank Gonzalez Rodriguez as Senior Clinical Trial Associate at Plus Therapeutics! He is looking forward to being on the sponsor side of our clinical trials and part of our clinical operations team....
Cancer Control Month
April is dedicated to raising awareness for cancer prevention and treatment throughout the US. 🎗️ At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers....
Happy Doctor’s Day
We want to thank all of the #doctors and Principal Investigators we get to work with to help us run our #clinicaltrials and provide #treatment options for #patients! They all are great supporters of our mission to solve the toughest challenges in #oncology 🩺...
CSF-01 Implementation
In case you missed it, we announced the validation & clinical implementation of our CSF-01 Leptomeningeal Cancer Cell Diagnostic. The CSF-01 cancer cell enumeration test is an exploratory endpoint in the ReSPECT-LM Phase 1 trial that has shown promise in the...
NCCN Curtain Raiser
❗Mark Your Calendars❗ Plus Therapeutics will be presenting a poster at the National Comprehensive Cancer Network Annual Conference Press release: https://bit.ly/PSTV_PR #NCCN #BrainCancer #Glioblastoma #BreastCancer #LungCancer #ClinicalTrials
Susan G. Komen: LM
Thank you to @SusanGKomen for adding "Leptomeningeal Metastasis" to your Breast Cancer Glossary patient resource! 🎗️ "Leptomeningeal Metastasis: Cancer that spreads from the original tumor to the meninges (the thin layers of tissue that cover and protect the brain and...
CSF-01 Announcement
BREAKING NEWS: Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic > Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and...
IR Events
Want to hear the latest milestones from our team? We have replays of all our events and earnings calls on our website at IR.PlusTherapeutics.com/Events. Questions about any of the recorded events? Contact us at https://ir.plustherapeutics.com/resources/contact-ir...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 PBC Funding Award
- 1.2 $3 Million DoD Grant
- 1.3 “Thriving Together”
- 1.4 Head for the Cure: North Texas
- 1.5 Welcome Dr. Brenner!
- 1.6 LBBC Curtain Raiser
- 1.7 PSTV Analysis
- 1.8
- 1.9 Welcome Brenner and Blouw
- 1.10 NCCN Poster
- 1.11 NCCN Curtain Raiser
- 1.12 Plus Approach
- 1.13 Welcome Frank
- 1.14 Cancer Control Month
- 1.15 Happy Doctor’s Day
- 1.16 CSF-01 Implementation
- 1.17 NCCN Curtain Raiser
- 1.18 Susan G. Komen: LM
- 1.19 CSF-01 Announcement
- 1.20 IR Events